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Simple Summary: Up to 50% of uveal melanoma patients subsequently develop metastases, for
which no effective treatment has been identified. In this study, 87.5% of uveal melanoma patients’
samples were positive for phosphorylated retinoblastoma (RB), and ex vivo incubation of patients’
biopsy specimens with CDK4/6 inhibitor decreased the phosphorylation of RB. Hepatocyte growth
factor (HGF), which is rich in the liver microenvironment, diminished the efficacy of CDK4/6
inhibitor. In human HGF knock-in NOD.Cg-Prkdc scid Il2rg tm1Wjl/SzJ mice, combination of
CDK4/6 inhibitor and cMET inhibitor showed significant growth suppression in implanted metastatic
uveal melanoma cells, compared to CDK4/6 inhibitor alone. Taken together, our preclinical study
indicated that combining CDK4/6 inhibitor and cMET inhibitor would provide significant clinical
benefit to patients with metastatic uveal melanoma.
Abstract: Uveal melanoma (UM) is the most common cancer of the eye in adults. Up to 50% of
UM patients subsequently develop metastases, especially in the liver. It has been reported that the
retinoblastoma (RB) pathway is deregulated in more than 90% of UM despite the rarity of mutations
in the RB1 gene itself. CDK4/6 inhibition (CDK4/6i) is a rational strategy for treatment of UM. In this
report, we investigated the antiproliferative activity of a selective CDK4/6 inhibitor on metastatic
UM. A CDK4/6 inhibitor suppressed UM cell lines growth in in vitro and in vivo experiments.
Hepatocyte growth factor (HGF) decreased the effect of CDK4/6 inhibitor on metastatic UM cell lines.
When CDK4/6i was combined with cMET inhibitor, enhanced growth suppression was observed in
metastatic UM tumors grown in human-HGF knock-in xenograft mouse models. HGF is enriched in
the liver and the majority of liver metastases from UM express activated forms of cMET; therefore,
signaling through cMET could contribute to the resistance mechanisms against CDK4/6i, especially
in UM patients with hepatic metastasis. Together, these results provide a rationale for the use of
cMET inhibitor in combination with a CDK4/6 inhibitor for the treatment of metastatic UM.
Keywords: CDK4/6 inhibitor; cMET inhibitor; metastatic uveal melanoma; combination therapy; HGF
1. Introduction
With an incidence of approximately two to eight cases per million per year in western
countries, uveal melanoma (UM) remains a rare malignancy that nevertheless represents
the most common primary intraocular tumor in adults [1]. Despite the development of
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effective local therapies, metastases occur in up to 50% of patients, predominantly in the
liver [2]. The reported median survival time of metastatic UM patients ranges from only
three to 12 months [3,4]. To improve the poor survival of patients with metastatic UM,
development of efficacious new therapeutic approaches is needed [4,5].
More than 80% of UM have mutations in the genes GNAQ and GNA11 (collectively
referred to as GNAQ/11), which encode small GTPases [6–8]. Oncogenic signaling as a
result of GNAQ/11 mutations activates the MEK-ERK, Hippo-YAP, and PI3K/AKT/mTOR
pathways [9–11]. Most notably, MAPK pathway inhibition with MEK inhibitors showed
growth suppression of metastatic UM cell lines [12,13] and was; therefore, expected to
be a viable therapeutic strategy. In a phase II trial, a MEK inhibitor, selumetinib, exhib-
ited a 15% partial response rate in metastatic uveal melanoma patients and improved
median progression-free survival (PFS), compared to a standard chemotherapy (15.9 ver-
sus 7.0 weeks, respectively). However, a subsequent phase III clinical trial (SUMIT trial),
comparing selumetinib in combination with dacarbazine versus dacarbazine alone, did not
meet its primary endpoint, because it showed a poor response rate and only a one-month
improvement in median PFS [14].
A potential explanation for the lack of efficacy of MEK inhibition in actual patients
could be a compensatory mechanism provided by the tumor microenvironment. Our group
reported that one such mechanism is mediated by hepatocyte growth factor (HGF) [15,16].
We reported that HGF induced resistance to MEK inhibition in UM [17,18]. HGF is primarily
produced in the liver and promotes the growth of various malignancies by increasing
angiogenesis, cell motility, and cell growth, as well as by inhibiting apoptosis [19–21].
Prior studies indicated that HGF might play an important role in mediating UM growth
and metastasis [15,16,22,23]. The receptor for HGF, cMET (mesenchymal-to-epithelial
transition factor), is a plasma membrane-localized tyrosine kinase receptor that is activated
by HGF [24] and expressed in human UM [16,25,26]. cMET expression was especially high
in metastatic tumors (80%) [25,26]. In addition, a significant association between cMET
expression and UM specific-mortality was noted [16].
Combination of MEK inhibitor with other signal blockades such as PKC inhibitor,
AKT inhibitor, or cMET inhibitor are theoretically reasonable to potentially increase clinical
efficacy in metastatic UM; however, MEK-based combination treatments are generally
more toxic and long-term treatment would be difficult. As an alternative approach, we
investigated the role of cyclin-dependent kinases (CDK) 4/6 inhibition in metastatic UM
as a downstream target for signal activation related to G-protein mutations. In most
UM cases, the retinoblastoma (RB) pathways are functionally inhibited although actual
mutations in the RB1 gene are rare [27,28]. As a result of cyclin D1 overexpression in about
65% of UM cases, the RB protein is constitutively hyperphosphorylated and functionally
inactivated [29]. Inactivation of p16INK4a (CDKN2A), an endogenous inhibitor of CDK4,
occurs frequently in primary UM (32%) and UM cell lines (50%) as a result of promoter
methylation [30]. In addition to driver mutations in GNAQ/11, these characteristics of UM
biology suggest that targeting CDK4/6 activity could be a valuable therapeutic strategy.
Our results here indicate that CDK4/6 inhibition has a potent anti-proliferative effect on
metastatic UM. We also demonstrated that HGF, rich in the tumor microenvironment in
the liver, reduces the effect of CDK4/6 inhibitor in UM. The addition of cMET inhibition to
the CDK4/6 inhibitor overcame the resistance mechanism induced by HGF.
2. Results
2.1. Abemaciclib Induces G1 Arrest and Decreases Cell Growth in Metastatic Uveal
Melanoma Cells
To investigate the potential impact of CDK 4/6 inhibitor on metastatic UM, we exam-
ined abemaciclib, a selective CDK4/6 inhibitor, on three metastatic UM cell lines derived
from UM metastases. Cells were treated with abemaciclib at concentrations ranging from
0.06 to 4.0 µmol/L for 48 h. This treatment reduced the phosphorylation and subsequent
activation of RB protein, which resulted in down-regulation of the E2F target genes and de-
creased cyclin A2 and FOXM1 proteins as well as the mRNAs of TOPO2 and TK1 (Figure 1A
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and Figure S1A). Additionally, abemaciclib treatment resulted in increased expression of cy-
clin D1 and CDK4 (Figure 1A), probably due to the compensatory mechanism for CDK4/6
signaling inhibition. Cell-cycle analysis demonstrated cell-cycle arrest at G0-G1 and a
decreased proportion of S phase following 24 h exposure to abemaciclib (Figure 1B). Finally,
abemaciclib reduced cell growth and cell viability in all three metastatic UM cell lines. The
GI50 values for abemaciclib ranged from 0.3 to 20 µmol/L (Figure 1C,D). UM002B and
UM004 were more sensitive to abemaciclib (GI50 = 0.43 and 0.37 µmol/L, respectively),
so these cell lines were used for subsequent investigations into the mechanism of action
of abemaciclib. Although it reduced the viability of the cell lines, abemaciclib treatment
for 48 h did not increase cleaved PARP levels, a cellular marker for apoptosis (Figure 1E).
These results indicate that abemaciclib elicits cytostasis and growth arrest, rather than
apoptosis, in monolayer cultures of metastatic UM cells.
2.2. RB Protein Is Phosphorylated in Metastatic Uveal Melanoma Tissues and Abemaciclib Inhibits
the Phosphorylation of RB in Metastatic UM Explants Obtained from Patients
Tumor biopsy samples from 16 UM patients with liver metastasis were stained with
anti-phospho-RB antibodies. Staining positivity was scored as 0, negative; 1+, positive
staining in <1% of tumor cells; 2+, in 1% to 10% of tumor cells; 3+, in >10% of tumor cells.
We observed positive staining of phospho-RB in 87.5% of samples (two patients, 0 staining;
two patients, 1+ staining; 10 patients, 2+ staining; two patients, 3+ staining). Representative
images of the progressive staining grades are depicted in Figure 2A. The scores of phospho-
RB were not correlated with survival rates of the patients. To test whether abemaciclib
inhibits the phosphorylation of RB in metastatic UM tissues, we analyzed UM patient
samples using an ex vivo treatment approach as previously described [18]. Tumor tissue
pieces obtained by biopsy were treated with dimethyl sulfoxide (DMSO) or 1 µmol/L
abemaciclib. As shown in Figure 2B, abemaciclib could reduce phospho-RB staining from
2+ to 0 in both patient samples. Treatment with abemaciclib inhibited the phosphorylation
of RB, supporting data obtained from in vitro experiments.
2.3. HGF Reduces the Growth-Inhibitory Effect of Abemaciclib in Metastatic Uveal
Melanoma Cells
HGF plays an important role in mediating UM growth and metastasis [15,16]. We
previously reported that HGF modulated the response to MEK inhibition in UM [18,19]. To
investigate the potential impact of HGF on the effects of CDK4/6 inhibitor in metastatic UM,
abemaciclib treatment was administered in the presence of HGF. HGF activated AKT and
ERK, and increased cell viability of UM002B and UM004 cells in a dose-dependent manner
(Supplementary Figure S2). HGF also reduced the effects of abemaciclib in cell viability
assays (Figure 3A). These data demonstrate that HGF, rich in the liver microenvironment,
can enhance the viability of metastatic UM cells that have been treated with a CDK4/6
inhibitor. To further investigate this rescue mechanism of HGF, UM002B and UM004 cells
were pretreated with abemaciclib for 48 h followed by stimulation with 10 ng/mL of
HGF. HGF did not affect the phosphorylation of RB induced by abemaciclib. However, it
increased the phosphorylation of p70S6k induced with abemaciclib treatment (Figure 3B).
p70S6k is a major downstream effector of mTORC1, which plays key roles in ribosome
biogenesis and mRNA translation [31]. Our data suggest that the enhanced activation
of p70S6K by HGF might compensate for the loss of cell division in abemaciclib-treated
cells and thus contribute to abemaciclib resistance in metastatic UM melanoma cells.
Furthermore, downstream activation of AKT and ERK by HGF was apparently not affected
by abemaciclib, suggesting that a different compensatory mechanism might exist in the
HGF-rich tumor microenvironment, and might play a prominent role in hepatic metastasis.
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Figure 1. Abemaciclib induces G1 arrest and decreases cell growth in metastatic uveal melanoma cells. (A) UM001, 
UM002B, and UM004 cells were treated with DMSO or different concentrations of abemaciclib as indicated for 48 h. Cell 
lysates were probed with phospho-retinoblastoma (RB), total RB, cyclin A2, FOXM1, cyclin D1, CDK4, and β-actin anti-
bodies. (B) Cells were treated with DMSO or 1 μM abemaciclib for 24 h. Cells were then fixed, permeabilized, and sub-
jected to PI staining. Cell-cycle analysis was performed with FlowJo software. ** p < 0.01, based on the two sample t-test 
Figure 1. Abemaciclib induces G1 arrest and decreases cell growth in metastatic uveal melanoma cells. (A) UM001, UM002B,
and UM004 cells ere treated with DMSO r different concentratio s of abemaciclib as indicate for 48 h. Cell lysates
were probed with phospho-retinoblastoma (RB), total RB, cyclin A2, FOXM1, cyclin D1, CDK4, and β-actin antibodies. (B)
Cells were treated with DMSO or 1 µM abemaciclib for 24 h. Cells were then fixed, permeabilized, and subjected to PI
staining. Cell-cycle analysis was performed with FlowJo software. ** p < 0.01, based on the two sample t-test with unequal
variance. (C) UM001, UM002B, and UM004 cells were treated with DMSO or different concentrations of abemaciclib as
indicated. After seven days, cells were subjected to crystal violet staining. Representative microscopic images of the cells at
×200 magnification are shown. Scale bar, 100 µm. (D) UM001, UM002B, and UM004 cells were seeded in 96-well plates
overnight and then treated with increasing doses of abemaciclib for 96 h. Cell viability was analyzed by the MTS assay.
GI50 values were calculated using Graph pad Prism. (E) UM001, UM002B, and UM004 cells were treated with DMSO or
different concentrations of abemaciclib as indicated for 48 h. Cell lysates were probed with PARP and β-actin antibodies.
Stau, UM004 cells were treated with 0.5 µM of staurosporine for 3 h as a positive control.
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Figure 2. The phosphorylation of RB in metastatic uveal melanoma and the effect of abemaciclib on inhibiting phosphor-
ylated RB in metastatic uveal melanoma (UM) explants. (A) Representative images (magnification, ×400) of phospho-RB 
Figure 2. The phosphorylation of RB in metastatic uveal elano a and the effect of abe aciclib on inhibiting phosphory-
lated RB in metastatic uveal melanoma (UM) explants. (A) Representative images (magnification, ×400) of phospho-RB
staining (red color arrow) illustrating the progressively increasing staining scores for metastatic samples of uveal melanoma
patients. Staining positivity was scored as 0, negative; 1+, positive staining in <1% of tumor cells; 2+, in 1% to 10% of tumor
cells; 3+, in >10% of tumor cells. (B) Fresh UM tumors obtained from surgery were cut into approximately 1 mm3 pieces
and plated on Vetspon absorbable hemostatic gelatin sponges for 48 h. The sponges were pre-soaked in medium containing
DMSO as a vehicle control and 1 µM abemaciclib. Medium was replenished every 24 h. Surgical specimen and tumor pieces
treated as above were formalin fixed and paraffin embedded. Tissue sections were stained with phospho-RB S807/811.
Representative images (magnification, ×400) of phospho-RB staining (red color arrows) are shown.
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Figure 3. Hepatocyte growth factor (HGF) reduces the growth-inhibitory effect of abemaciclib in metastatic uveal mela-
noma cells. (A) Cells were exposed to various concentrations of abemaciclib as indicated with or without 10 ng/mL of HGF 
for 96 h and cell survival was assessed by the MTS assay. Data are presented as mean ± SD. (B) Cells were exposed to 
various concentrations of abemaciclib as indicated with or without 10 ng/mL of HGF for 48 h. Cells were lysed and phos-
phorylation of cMET, RB, AKT, ERK, and p70S6K was assessed by Western immunoblotting. 
Figure 3. Hepatocyte growth factor (HGF) reduces the growth-inhibitory effect of abemaciclib in metastatic uveal melanoma
cells. (A) Cells were exposed to various concentrations of abemaciclib as indicated with or without 10 ng/mL of HGF for
96 h and cell survival was assessed by the MTS assay. Data are presented as mean ± SD. (B) Cells were exposed to various
concentrations of abemaciclib as indicated with or without 10 ng/mL of HGF for 48 h. Cells were lysed and phosphorylation
of cMET, RB, AKT, ERK, and p70S6K was assessed by Western immunoblotting.
2.4. Merestinib Overcomes HGF-Mediated Resistance to Abemaciclib in Metastatic Uveal
Melanoma Cells
To investigate whether targeting cMET could abrogate HGF-mediated resistance to
abemaciclib in UM cells, we tested merestinib, a type-II ATP competitive inhibitor of the
cMET tyrosine kinase [32]. In UM002B and UM004 cells, merestinib blocked HGF-induced
cMET phosphorylation in a dose-dependent manner (Figure 4A). At a concentration less
than 3.2 µmol/L, merestinib alone did not affect viability of either UM002B or UM004
cells (Supplementary Figure S3). UM cells were treated with abemaciclib alone or in
combination with merestinib, in the presence or absence of HGF. As shown in Figure 4B,C,
HGF partially restored the viability and cell proliferation of abemaciclib-treated UM cells,
an effect that was blocked by merestinib. The phosphorylation of cMET and downstream
activation of AKT and ERK1/2, induced by HGF, were blocked by merestinib treatment.
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Additionally, phosphorylation of p70S6K, induced by abemaciclib and enhanced by HGF,
were downregulated by merestinib (Figure 4D). Taken together, these results demonstrate
that cMET inhibition reverses the HGF-mediated resistance to abemaciclib.




Figure 4. Merestinib overcomes HGF-mediated resistance to abemaciclib in metastatic uveal melanoma cells. (A) UM002B 
and UM004 cells were treated with merestinib for 4 h, followed by 10 ng/mL of HGF stimulation for 15 min. Phosphory-
lation of cMET was evaluated by Western immunoblotting of cell lysates with phospho-cMET antibody. Actin was used 
as the loading control. (B) UM002B and UM004 cells were treated with DMSO or 1 μM abemaciclib, in combination with 
10 ng/mL of HGF and/or 0.2 μM merestinib for 4 days. Cell viability was determined by the MTS assay. Data are presented 
as mean ± SD. ** p < 0.01, based on the two sample t-test with unequal variance. (C) UM002B and UM004 cells were treated 
with DMSO or 1 μM abemaciclib, in combination with 10 ng/mL of HGF and/or 0.2 μM of merestinib for seven days. Cells 
were stained and representative images are shown. (D) UM002B and UM004 cells were pretreated with DMSO, 1 μM of 
abemaciclib, or 0.2 μM of merestinib for 48 h. Cells were then stimulated with 10 ng/mL HGF for 1 h, as indicated. Acti-
vation of cMET, RB, AKT, ERK1/2, and p70S6K was analyzed by Western immunoblotting. 
  
Figure 4. Merestinib overcomes HGF-mediated resi tance to a lib in metastatic uveal melanoma cells. (A) UM002B
and UM004 cells were treated with merestinib for 4 h, followed by 10 ng/mL of HGF stimulation for 15 min. Phosphorylation
of cMET was evaluated by Western immunoblotting of cell lysates with phospho-cMET antibody. Actin was used as the
loading control. (B) UM002B and UM004 cells were treated with DMSO or 1 µM abemaciclib, in combination with 10 ng/mL
of HGF and/or 0.2 µM merestinib for 4 days. C ll viability was determined by the MTS assay. Data ar presented as
mean ± SD. ** p < 0.01, b s d on the tw sample t-test with unequal variance. (C) UM002B and UM004 cells were treated
with DMSO or 1 µM abemaciclib, in combination with 10 ng/mL of HGF and/or 0.2 µM of merestinib for seven days.
Cells were stained and representative images are shown. (D) UM002B and UM004 cells were pretreated with DMSO, 1 µM
of abemaciclib, or 0.2 µM of merestinib for 48 h. Cells were then stimulated with 10 ng/mL HGF for 1 h, as indicated.
Activation of cMET, RB, AKT, ERK1/2, and p70S6K was analyzed by Western immunoblotting.
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2.5. Merestinib Inhibits the HGF-Mediated Protection from Cellular Senescence in
Abemaciclib-Treated Uveal Melanoma Cells
CDK4/6 inhibitor induces cytostasis that is mediated by G1 arrest and senescence. One
possible mechanism of CDK4/6 inhibitor-induced senescence is through downregulation
of the FOXM1 transcription factor [33]. On the other hand, HGF/cMET signaling stimulates
the expression and transcriptional activity of FOXM1 via the RAS/ERK1/2, PI3K/AKT,
and STAT3 signaling pathways [34,35]. We; therefore, investigated whether abemaciclib
induces senescence in UM cells via downregulation of FOXM1. We also investigated
whether HGF/cMET signaling interferes with this effect. As shown in Figure 5, significant
increases in the percentage of SA-β-gal positive cells were found in UM002B and UM004
cells treated with abemaciclib and HGF could reduce the number of SA-β-gal positive cells.
Merestinib reversed the reduction of the senescence-associated marker SA-β-gal-positivity
mediated with HGF. We further analyzed the effect of HGF/cMET signaling on FOXM1
expression. Even under abemaciclib treatment, the expression of FOXM1 was increased by
HGF and was accompanied by the phosphorylation of cMET and the activation of AKT
and ERK1/2 (Figure 5B). HGF increased FOXM1 in a dose-dependent manner in UM004
cells treated with abemaciclib (Supplemental Figure S4). Merestinib treatment reversed
these changes in FOXM1 expression (Figure 5B). FOXM1 is considered to be the key
element of HGF-mediated protection of UM cells from cellular senescence, and silencing
of FOXM1 expression resulted in loss of HGF-mediated protection. Whereas control cells
were protected from abemaciclib-induced senescence by HGF, FOXM1 knockdown resulted
in loss of this protective function (Figure 5C,D). Thus, FOXM1 contributes to the HGF-
mediated protection from senescence in uveal melanoma cells treated with a CDK4/6
inhibitor.
2.6. Abemaciclib in Combination with Merestinib Inhibits Metastatic Uveal Melanoma Tumor
Growth in NSG-hHGFki Mice
Since stimulatory effects of mouse HGF on human cMET are weak, the role of HGF
would be difficult to examine using traditional xenogeneic mouse models. In fact, mouse
recombinant HGF did not increase the viability of UM004 cells and did not activate cMET
at Tyr1349, one of the multidocking sites for recruiting downstream adaptor molecules [36].
Mouse HGF-activated signal transduction to downstream AKT and ERK in UM004 cells
was either absent or very weak although cMET was phosphorylated at T1234/1235 (Sup-
plemental Figure S5). To overcome this limitation, the efficacy of the abemaciclib and mer-
estinib combination was examined in NOD.Cg-Hgftm1.1(HGF)Aveo Prkdcscid IL2rgtm1Wjl/J
(NSG-hHGFki) mice that produce human HGF. The concentration of serum human HGF
in NSG-hHGFki mice measured by ELISA (Abcam) was 12.0 ± 0.58 (S.D) ng/mL. NSG-
hHGFki mice bearing implanted UM004 cells were treated with either vehicle, abemaciclib
(50 mg/kg), merestinib (12 mg/kg), or a combination of abemaciclib and merestinib. Both
abemaciclib and merestinib alone inhibited tumor growth, and the combination yielded
greater inhibition of tumor growth than either treatment alone (Figure 6A,B). No signifi-
cant changes in body weight were found between the four groups during the treatment
period (Figure 6C). To elucidate further the conceptual mechanism of the abemaciclib
and merestinib combination, tumors resected following seven days of treatment were
analyzed by Western immunoblot and immunohistochemistry (IHC). Treatment of mice
with abemaciclib resulted in inhibition of phosphorylated RB. Treatment of mice with
merestinib resulted in inhibition of phospho-cMET. As expected, FOXM1 was effectively
decreased by the abemaciclib and merestinib combination as compared to either treatment
alone (Figure 6D,E). Assessment of the Ki67 proliferation marker by IHC confirmed that
proliferative activity was suppressed in tumors treated with the abemaciclib and meres-
tinib combination. Taken together, these results suggest that the addition of merestinib
to abemaciclib enhances the suppression of UM growth in the tumor microenvironment
where human HGF is produced.
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Figure 5. HGF prevents abemaciclib induced-cell senescence and merestinib reverses HGF effects. (A) UM002B and 
UM004 cells were treated with DMSO or 1 μM of abemaciclib, in combination with 10 ng/mL of HGF and/or 0.2 μM of 
merestinib for six days. Cells were fixed and stained overnight for senescence-associated β-galactosidase activity. Positive 
cells were shown with arrows. Data are presented as mean ± SD. *, p < 0.05; **, p < 0.01, based on Tukey analysis. (B) 
UM002B and UM004 cells were treated with 1 μM of abemaciclib, in combination with 10 ng/mL of HGF and/or 0.2 μM 
of merestinib for 72 h. Activation of cMET, RB, FOXM1, AKT, ERK1/2, and p70S6K was analyzed by Western immunob-
lotting. (C) UM004 cells were transfected with control or FOXM1 targeting siRNA (#1 and #2) and cultured with 1 μM of 
Figure 5. HGF prevents abemaciclib induced-cell senescence and merestinib reverses HGF effects. (A) UM002B and UM004
cells were treated with DMSO or 1 µM of abemaciclib, in combination with 10 ng/mL of HGF and/or 0.2 µM of merestinib
for six days. Cells were fixed nd stained overnight for senescence-associated β-galactosidase activit . Posit ve cells were
shown with arrows. Data are presented as mean ± SD. *, p < 0.05; **, p < 0.01, based on Tukey analysis. (B) UM002B and
UM004 cells were treated with 1 µM of abemaciclib, in combination with 10 ng/mL of HGF and/or 0.2 µM of merestinib
for 72 h. Activation of cMET, RB, FOXM1, AKT, ERK1/2, and p70S6K was analyzed by Western immunoblotting. (C)
UM004 cells were transfected with control or FOXM1 targeting siRNA (#1 and #2) and cultured with 1 µM of abemaciclib
in the presence or absence of 10 ng/mL of HGF for six days. Following six-day treatment, cells were fixed and stained
overnight for senescence-associated b-galactosidase activity. Positive cells were shown with arrows. Knockdown of FOXM1
reversed the evasion of cellular senescence mediated by HGF. (D) UM004 cells were transfected with control or FOXM1
targeting siRNA (#1 and #2) in the presence of 1 µM of abemaciclib and 10 ng/mL of HGF for 72 h. FOXM1 and β-actin
were analyzed by Western immunoblotting.
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in human HGF knockin mice. (A) Mice bearing subcutaneous UM004 tumors were dosed with vehicle (n = 5), 50 mg/kg
abemaciclib (n = 5), 12 mg/kg merestinib (n = 5), or abemaciclib plus merestinib combination (n = 5) once daily for
28 days. Tumor size was measured by caliper twice weekly. (B) Tumor weight. Data represent mean volume ± SD.
* p < 0.05; ** p < 0.01, based on Dunnett’s test. (C) Average percentage change in body weight after treatments. (D) UM004
tumors were excised from mice following seven-day treatment. Tumor lysates were prepared and analyzed by Western
immunoblotting using phospho-cMET, cMET, phospho-RB, total RB, FOXM1, and β-actin. (E) Representative images
of immunohistochemical staining for hematoxylin and eosin (H & E), IgG isotype control, phospho-cMET, phospho-RB,
FOXM1, and Ki67 in UM004 tumor xenografts. Original magnification, ×400. Scale bar, 50 µm.
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3. Discussion
Due to the high cyclin D1 and RB expression observed in UM [28–30], the CDK4/6 in-
hibitor is a potentially attractive anticancer therapy for metastatic UM. In fact, we observed
phosphorylation of RB in 87.5% of tumor biopsy specimens obtained from metastatic UM
patients, consistent with a previous report [28]. In this study, we demonstrated the thera-
peutic potential of the CDK4/6 inhibitor, abemaciclib, in treating metastatic UM. The data
presented here show that CDK4/6 inhibitor is a viable therapeutic strategy in metastatic
UM. Using abemaciclib, we observed RB hypophosphorylation, cell-cycle arrest, cellular
senescence, and tumor growth reduction in metastatic UM in vitro, in vivo, and ex vivo.
Despite potential efficacy demonstrated by in vitro and in vivo experiments, CDK4/6
inhibitors as single agents for cancer treatment do not appear to be very effective [37].
Although CDK4/6 inhibitor induces cell-cycle arrest accompanied by senescence, a small
subpopulation of cells continually reenter the cell cycle, generating cells that escape from
senescence and retain their growth capacity [38,39]. Various combination strategies have
been investigated in the preclinical and clinical settings. Both PI3K/mTOR inhibitors and
RAF/MEK inhibitors are being explored as potential partners of CDK4/6 inhibitor. In
preclinical studies, CDK4/6 inhibitor, palbociclib, had an additive effect on cell death
in pancreatic ductal carcinoma cell lines when combined with MEK or PI3K/mTOR in-
hibitors [40]. Combination of CDK4/6 inhibitors with RAF/MEK inhibitors is an especially
promising therapeutic approach, particularly in patients with melanoma. Concurrent
targeting of both CDK4/6 and MEK resulted in enhanced cell death in both BRAF- and
NRAS-mutant melanoma [41]. Additionally, melanoma cell lines and tumor models that
are resistant to the BRAF inhibitor vemurafenib exhibit reactivated MAPK signaling and
upregulated cyclin D1, and are sensitive to abemaciclib treatment [42]. Despite conceptual
merits in combining CDK4/6 inhibitor with other signal blockades, a MEK inhibitor might
not be a good partner for CDK4/6 inhibitor in metastatic UM due to their class-specific
and potentially serious side effects, including cardiac and eye damage.
It should also be emphasized that the tumor microenvironment, especially in the
liver, might hamper the efficacy of CDK4/6 inhibitor. Emerging evidence indicates that
factors from the tumor microenvironment including HGF play a significant role in the
regulation of UM cells and their acquired resistance mechanisms to targeted therapies
such as MEK inhibition [17,18]. This issue was not well addressed previously due to
species-specificity of HGF. As reported in this paper, mouse HGF does not activate human
cMET signal transduction to downstream AKT and ERK; therefore, the influence of human
HGF signaling on efficacy of other signaling inhibitors cannot be tested in traditional
immuno-compromised mouse models. In this regard, our mouse model is unique by
testing a human “metastatic” UM cell line in NSG-hHGFki mice. As demonstrated in this
report, human HGF reduces the growth-inhibitory effect of abemaciclib on metastatic UM
cells in NSG-hHGFki mice.
HGF is abundant in the liver microenvironment and could contribute to the resistance
mechanism to various targeted anticancer agents [17,18]. In the present study, HGF was
shown to enhance mTOR activity in metastatic UM cells treated with abemaciclib. p70S6K
in the mTOR pathway was stimulated with abemaciclib. mTOR activation might occur
as a consequence of accumulated lysosomes and increased amino acid pools caused by
the metabolic reprogramming by CDK4/6 inhibitor, and HGF could further amplify this
mTOR effect by activating AKT and ERK [43,44]. In this regard, combination of CDK 4/6
inhibitor with cMET inhibitor is expected to be more efficacious.
Previous observations also suggest that cyclin D1 may inhibit TSC2, a negative regula-
tor of mTOR, in a CDK4/6-independent manner [45]. Our results and others have shown
that CDK4/6 inhibitors can lead to the accumulation of cyclinD1 to high levels [46,47]. To
test whether this accumulation of cyclin D1 is associated with the activation in p70S6K,
we silenced cyclin D1 expression in the cells treated with CDK4/6 inhibitor and HGF.
Knockdown of cyclin D1 did not alter the activation of p70S6K (Supplemental Figure S6);
therefore, accumulation of cyclin D1 does not appear to be associated with the CDK4/6
Cancers 2021, 13, 1104 12 of 17
inhibitor induced-mTOR activation. Together, these data highlight the possibility that HGF
might enhance the resistant response to CDK4/6 inhibitor through the activation of mTOR,
which might provide additional resistance to CDK4/6 inhibitor.
HGF/cMET signaling stimulates the expression and transcriptional activity of FOXM1
via its downstream pathways in pancreatic ductal adenocarcinoma and lung adenocar-
cinoma cells [34,35]. The activity of FOXM1, leading to suppression of cellular senes-
cence [48], is also influenced by CDK4/6 signaling [33]. In neuroblastoma cells, CDK4/6
inhibition caused cell-cycle arrest and cellular senescence that was correlated with dose-
dependent decreases in phosphorylated RB and FOXM1, respectively [49]. The present
study shows that HGF increased FOXM1 and decreased the percentage of senescent SA-β-
gal positive cells even during abemaciclib treatment. In FOXM1 knockdown cells, HGF
did not decrease SA-β-gal positive cell rate, implying that HGF protects UM cells from
CDK4/6 inhibitor induced-cellular senescence via upregulation of FOXM1, whereas cMET
inhibition reverses this HGF-mediated protective effect. Consistently, the combination
therapy with both abemaciclib and merestinib decreased FOXM1 to the lowest level among
the four treatment groups and inhibited tumor growth significantly in hHGF-knock-in
NSG mouse models.
4. Materials and Methods
4.1. Reagents
A CDK4/6 inhibitor, Abemaciclib (LY2835219), and a cMET inhibitor, merestinib
(LY2801653), were provided by Eli Lilly and Company, Indianapolis, IN, USA. Abemaciclib
and merestinib were dissolved in dimethyl sulfoxide (DMSO) to a 10 mmol/L concentration
and stored in small aliquots at −20 ◦C until further use. DMSO was used as solvent control.
Recombinant Human HGF (rhHGF) was purchased from R & D systems, Minneapolis,
MN, USA. Antibodies against cMET, phospho-cMET (T1234/1235), AKT, phospho-AKT
(S473), ERK1/2, phospho-ERK1/2, RB, phospho-RB(S780), phospho-RB(S807/811), CDK4,
cyclin A2, cyclin D1, p70 S6K, phospho-p70 S6K (T389), PARP, FOXM1 and β-actin were
purchased from Cell Signaling Technology, Beverly, MA, USA. An antibody against Ki67
was purchased from DAKO, Cupertino, CA, USA.
4.2. Cell Lines
UM001, UM002B, and UM004 were established in our laboratory and authenticated
by DDC Medical, Fairfield, OH, USA. Detailed mutational analysis of these cell lines was
performed by TruSeq (Illumina, San Diego, CA, USA) (Supplementary Table S1A).
UM001 and UM004 cells were cultured according to the methods reported [50].
UM002B cells were maintained in MEM medium containing 15% heat-inactivated FBS and
penicillin–streptomycin.
4.3. Short-Interfering RNA and Transfection
UM004 cells (5 × 105) were seeded in 6-well plates. The next day, cells were trans-
fected for 4 to 6 h with chemically synthesized short-interfering RNAs (siRNA) at a final
concentration of 10 nmol/L using Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA,
USA) according to manufacturer’s instructions. The following siRNAs were purchased
from Thermo Fisher Scintific, Waltham, Massachusetts, USA.
FOXM1 siRNAs (#1: AUAGGUACCAGGUAUGAGCTG; #2: UAGGUAUUGUU-
GAUAGUGCA).
Cyclin D1 siRNAs (#1:UCUGGUAUCAAAAUGCUCCGG).
The non-targeting siRNA, Silencer Select Negative Control no.1 siRNA (Thermo Fisher
Scientific), was used as a control.
4.4. MTS Assays
Cells were plated overnight at 3 × 103 per well in 96-well plates and treated with 0.0625
to 16 µmol/L of abemaciclib, 0.2 µmol/L of merestinib, or 10 µg/mL of rhHGF. Following
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a 96-hr drug exposure, cell viability was assessed using the CellTiter 96 Aqueous One kit
(Promega Corporation, Madison, WI, USA) according to the manufacturer’s instructions.
Experiments were performed in triplicate. GI50 values were calculated using Graph Pad
Prism7 software (Grapfpad Software, San Diego, CA, USA).
4.5. Cell Growth Assays
Cells were plated 1 × 105 per well in 6-well plates. On the next day, HGF or individual
inhibitors were added. Cells were cultured for an additional 7 days (medium and additives
were replenished once on day 4). After fixation with 3.7% paraformaldehyde, cells were
stained with 0.05% crystal violet solution for 30 min. Wells were thoroughly washed in
distilled water and air-dried. Experiments were performed in triplicate. Plates were imaged
by scanning while images were captured at ×200 magnification on a Nikon™ Eclipse 50i
microscope (Nikon, Tokyo, Japan) with NIS-Elements D 3.1 software (Nikon).
4.6. Cell-Cycle Analysis
Cells were plated 1 × 106 per well in 6-well plates. On the next day, cells were treated
with 1 µmol/L of abemaciclib or DMSO for 24 h. Cells were detached with phosphate-
buffered saline-EDTA, washed with cold PBS, and resuspended in 0.5 mL of cold PBS
to make a single-cell suspension. Cells were then fixed in 4.5 mL of 70% ethanol for 2 h,
followed by centrifugation at 800 g for 5 min. Cell pellets were washed with cold PBS and
resuspended in 1 mL of 0.1% (v/v) Triton X-100 staining solution containing 100 ng/mL
of RNase and 40 mg/mL of propidium iodide for 30 min at room temperature. Stained
cells were then analyzed by flow cytometry on a BD FACSCalibur flow cytometer (BD
Biosciences, San Jose, CA, USA). Experiments were performed in triplicate. Data were
analyzed using FlowJo software version 9.6 (TreeStar, Ashland, OR, USA).
4.7. Protein Extraction and Western Immunoblotting
Cells and tumor samples were lysed on ice in M-PER Mammalian Protein Extraction
Reagent (Thermo Fisher Scientific) with combined protease and phosphatase inhibitor cock-
tails (Thermo Fisher Scientific). Total protein was quantified using the BCA protein assay
(Thermo Fisher Scientific). Equal amounts of protein (20 µg) were loaded and fractionated
using a 4–20% SDS-PAGE Gel (Thermo Fisher Scientific) for Western immunoblotting
assays. The protein was transferred onto PVDF membranes (Thermo Fisher Scientific).
Membranes were blocked with SuperBlock T20 (TBS) blocking buffer (Thermo Fisher
Scientific) and incubated with indicated primary antibodies overnight at 4 ◦C. Targeted
proteins were detected using horseradish peroxidase-conjugated secondary antibodies
followed by development using chemiluminescence substrate (Thermo Fisher Scientific).
The immunoreactive bands were visualized using MSP Brand blue autoradiography film
(MedSupply Partners, Atlanta, GA, USA). The quantitation of the protein bands inten-
sity was analyzed by ImageJ software (NIH, Bethesda, Maryland, USA). The bands were
normalized by β-actin.
4.8. Senescence Assay
Cellular senescence was assayed via measurement of senescence-associated β-
galactosidase activity (SA-β-gal). Cells were plated at 1 × 105 per well in 6-well plates. On
the following day, HGF and/or signal inhibitors were added. Cells were cultured for an
additional 6 days, and then fixed and stained overnight according to the manufacturer’s
protocol (Cell Signaling #9860). Cells were imaged for SA-β-gal using a Nikon Eclipse 50i
microscope (Nikon) with NIS-Elements D 3.1 software (Nikon). The percentage of SA-β-gal
positive cells was determined by counting the number of positive cells present in 3 separate
microscope frames and comparing to the total number of cells.
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4.9. Xenograft Therapeutic Trials
NOD.Cg-Hgftm1.1(HGF)Aveo Prkdcscid IL2rgtm1Wjl/J (NSG-hHGFki) mice were pur-
chased from the Jackson Laboratory, Bar Harbor, Maine, USA and bred and kept in filter-top
cages at 22 ◦C, 60% humidity in our animal facility. Sterile food and water were accessible
ad lib. UM004 cells (2 × 106) were injected subcutaneously in male and female 8- to 10-week-
old mice and kept in the same conditions. UM004 xenograft was selected for this study
because UM004 cells are sensitive to the CDK4/6 inhibitor, abemaciclib, and they grow
stably in NSG-hHGFki mice. In NSG-hHGFki mice used in this experiment, human HGF is
produced in any organ; therefore, the location of tumor implantation is not critical for the
blocking experiments of HGF. Since consecutive accurate measurements of tumors are diffi-
cult in orthotopic liver metastasis model, we decided to use the subcutaneous implantation
model to investigate the efficacy of study medications in metastatic uveal melanoma in the
presence of human HGF. When tumor sizes reached approximately 100 mm3, mice were
randomized by tumor size and subjected to each treatment. At least 5 mice per treatment
group were included. Each group of mice was dosed via daily oral gavage with vehicle,
abemaciclib (50 mg/kg/day), merestinib (12 mg/kg/day), or a combination of both for a
total of 28 days. The abemaciclib was dissolved in 1% HEC in 20 mM phosphate buffer
(pH 2.0). The merestinib was dissolved in 10%PEG400/90%(10% Captisol in H2O). Tumor
size and body weight were measured twice and once a week, respectively. Tumor volumes
were calculated using the following formula: V = (L × W2)/2 (L, Length; W, width). All
procedures involving animals were reviewed and approved by the Institutional Animal
Care and Use Committee of Thomas Jefferson University.
4.10. Immunohistochemistry
UM004 xenografts were excised from mice following seven days of treatment with
vehicle, abemaciclib, merestinib, or in combination, fixed in formalin overnight and then em-
bedded in paraffin. After sectioning, paraffin-embedded tissue sections were deparaffinized
and antigen retrieval was accomplished using high pH conditional buffer. Sections were
incubated with anti-phospho-cMET, phospho-RB, FOXM1, and Ki67 antibody overnight.
On the following day, sections were incubated for 30 min in ImmPRESS AP Reagent (Vector
Laboratories, Burlingame, CA, USA), followed by incubating for 5 to 10 min in Imm-
Pact Vector Red (Vector Laboratories). Sections were counterstained with hematoxylin.
Immunohistochemistry analysis was performed in three tumors from each group.
4.11. Patient Tissue Samples
UM metastatic tumor samples were formalin-fixed and paraffin-embedded imme-
diately following biopsies. IHC was performed using the anti-phospho-RB (S807/811)
antibody. Tissue sections were read independently by two investigators (Kengo Saito
and Masahiro Ohara, Department of Medical Oncology, Thomas Jefferson University)
blinded to clinical information of individual patients. The percentage of positive cells
was determined by counting at least 200 cells at hot spot areas for each specimen. Four
staining categories were established—0 (no detectible staining), 1+ (positive staining in
<1% of tumor cells), 2+ (positive staining in 1–10%), and 3+ (positive staining in >10% of the
tumor cells). Patient samples were collected under a protocol approved by the Institutional
Review Board (IRB) of Thomas Jefferson University (IRB protocol number: # 11E.548).
4.12. Ex Vivo UM Explants
Human metastatic UM tissue was collected after obtaining patient consent for usage
of their biopsy specimens for research (IRB protocol number: #02.9014R). Less than 16 h
post-surgery, excess adipose and stromal tissue was removed and the tumors (explants of
Patient No.1 = Ex1 and Patient No.2 = Ex2) were cut into 1 mm3 pieces. Vetspon absorbable
hemostatic gelatin 1 cm3 sponges (Novartis, Basel, Switzerland) were pre-soaked in 12-well
plates for 15 min at 37 ◦C in 500 µL of MEM medium containing 10% FBS, penicillin-
streptomycin, and abemaciclib. DMSO was used as a vehicle control. To avoid concerns
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regarding intra-tumoral heterogeneity, up to four 1 mm3 pieces from different locations
of the original tumor were processed per sponge per treatment condition. Samples were
treated for 48 h with medium being replaced after 24 h. Tumor pieces were then formalin
fixed for IHC. Mutational status of these patient specimens is as follows: Ex1, GNAQ
Q209L, BAP1 wt, SF3B1 wt; Ex2, GNAQ Q209L, BAP1 wt, SF3B1 wt.
4.13. Statistical Analysis
Statistical analyses were performed using Graph Pad Prism7 software (Grapfpad
Software, San Diego, CA, USA). The data were expressed as the mean ± standard deviation.
Differences between two groups were analyzed using the two sample t-test with unequal
variance. All of the groups were determined to be normally distributed using Shapiro–Wilk
test (P > 0.05). One-way ANOVA analyses were performed to compare the means among
multiple groups. Post-hoc Dunnett’s or Tukey’s multiple comparison tests were performed
to determine statistical significance.
5. Conclusions
We present several lines of evidence that HGF mediates resistance to CDK4/6 inhibitor
in metastatic UM cells through activation of distinct cellular mechanisms. With respect to
future preclinical and clinical development, we provide proof-of-principle that targeting
HGF signaling overcomes the resistance elicited by HGF. We also present evidence that
combination therapy involving both CDK4/6 and cMET inhibitions is significantly more
effective than single-agent approaches in hHGF knock-in mice. Based on the present
study, abemaciclib in combination with merestinib should be warranted for further clinical
evaluation in the treatment of metastatic UM.
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